Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
Personalis has partnered with Cancer Research UK's Cancer Research Horizons, University College London, and the Francis Crick Institute to utilize its NeXT Personal liquid biopsy assay in the TRACERx study, aiming to improve early detection of lung cancer recurrence after surgery. The NeXT Personal assay offers high sensitivity in identifying circulating tumor DNA (ctDNA) in blood samples, enabling earlier detection of residual disease. This collaboration seeks to enhance patient care by tracking minimal residual disease (MRD) and providing insights for more informed treatment decisions in lung cancer patients.
- Collaboration with renowned institutions enhances credibility.
- NeXT Personal assay shows high sensitivity for ctDNA detection.
- Potential to improve early detection of lung cancer recurrence.
- Focus on tracking minimal residual disease could lead to better patient outcomes.
- None.
Personalis’ NeXT Personal® liquid biopsy assay will be deployed in a collaboration for TRACERx to assess approaches for earlier lung cancer recurrence post-surgery and for relapse
Previously reported findings from the TRACERx study have transformed our understanding of the evolution of the most common type of lung cancer, non-small cell lung cancer (NSCLC), and the TRACERx research team is taking practical steps to make precision medicine for lung cancer patients a reality. The study will utilize Personalis’ NeXT Personal assay, which has demonstrated high sensitivity for detecting a key marker – circulating tumor DNA (ctDNA) – from a patient’s blood sample, with the goal of enabling earlier detection of residual or recurrent cancer.
The current standard of care for NSCLC relapse detection is primarily focused on imaging modalities such as the CT scan, which are known to be limited in their sensitivity. The collaboration is focused on addressing this challenge through advanced ctDNA analysis. As part of TRACERx, the teams will use NeXT Personal to identify and track minimal residual disease (MRD) in patients post-surgery, potentially before relapse is detected through standard of care technologies.
“Thanks to the TRACERx study, we’ve already seen the importance of ctDNA in predicting cancer recurrence in an initial cohort of patients,” said Professor
"The TRACERx study is greatly advancing our understanding of lung cancer and cancer biology more broadly. Our high sensitivity NeXT Personal MRD assay is uniquely poised to support the study by providing insights about how tumor biology changes over time and by enabling earlier detection of MRD and cancer recurrence. We believe this collaboration will ultimately contribute to an advanced standard of care for cancer patients," said
About NeXT Personal
NeXT Personal is a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify MRD and recurrence in patients previously diagnosed with cancer. The assay is designed to deliver industry-leading MRD sensitivity down to the 1 part-per-million range, an approximately 10- to 100-fold improvement over other available technologies. It leverages whole genome sequencing of a patient’s tumor to identify up to 1,800 specially selected somatic variants that are subsequently used to create a personalized liquid biopsy panel for each patient. This may enable earlier detection across a broader variety of cancers and stages, including typically challenging early-stage, low mutational burden, and low-shedding cancers. NeXT Personal is also designed to simultaneously detect and quantify clinically relevant mutations in ctDNA that may be used in the future to help guide therapy when cancer is detected. These include known targetable cancer mutations, drug resistance mutations, and new variants that can emerge and change over time, especially under therapeutic pressure.
About
At
About TRACERx Study
TRACERx (Tracking Cancer Evolution through therapy (Rx)) lung study is the single biggest investment in lung cancer research by
About Cancer Research Horizons
-
Cancer Research Horizons is the innovation engine of
Cancer Research UK – the world’s largest charitable funder of cancer research. - We bring together world-leading minds, bold ideas and the right partners to bridge the gap between research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.
- To date, we’ve played an instrumental role in forming over 60 spin-out companies.
- We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients across the world.
-
With access to Cancer Research UK’s network of 4000 exceptional researchers, and
£400 + million of annual research spend, we’re a powerful partner in the fight to conquer cancer. - Cancer Research Horizons is the second biggest oncology out-licensor globally.
- By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, licensing and collaboration, spin out creation, and offer a full spectrum of drug discovery and clinical capabilities.
- Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered.
- For more information and to get in touch with the team, visit www.cancerresearchhorizons.com
About
-
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information. - Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
-
Cancer Research UK has been at the heart of the progress that has already seen survival in theUK double in the last 40 years. -
Today, 2 in 4 people survive their cancer for at least 10 years.
Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034. -
Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors and nurses. -
Together with its partners and supporters,
Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer.
Cancer research
About UCL – London’s
UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities. Since 1826, we have championed independent thought by attracting and nurturing the world's best minds. Our community of more than 43,800 students from 150 countries and over 14,300 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems. We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact. We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors. For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge. We were the first in
About
The
Personalis Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of
View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005181/en/
Investor Relations Contact for
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for
pr@personalis.com
www.personalis.com
650-752-1300
Source:
FAQ
What is the purpose of the Personalis NeXT Personal assay in the TRACERx study?
Which organizations are collaborating with Personalis for the TRACERx study?
How does the NeXT Personal assay improve lung cancer diagnostics?
What type of cancer is the focus of the TRACERx study?